New drug MDI-2517 put to the test in first human safety trial
NCT ID NCT07220889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new drug called MDI-2517 in 32 healthy adults aged 18 to 55. Participants received either a single or multiple doses of the drug or a placebo. Researchers monitored side effects, lab results, vital signs, and how the drug moves through the body. The study is complete, but it only looked at safety and drug levels, not whether the drug treats any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MDI-2517
- What could go wrong
- This is a very early Phase 1 trial with only 32 healthy people, so it cannot tell us if the drug works for any disease. The main goal is just safety, and many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AFTER ORAL INTAKE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
1951 NW 7th Avenue, Suite 180
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.